The Therapeutic Effects of Peroneal Nerve Functional Electrical Stimulation for Lower Extremity in Patients With Sub-acute Post-stroke Hemiplegia (RALLY)
The Therapeutic Effects of Peroneal Nerve Functional Electrical Stimulation for Lower Extremity in Patients With Sub-acute Post-stroke Hemiplegia A Randomized Controlled Study
Among the sequelae of stroke, gait disorder is directly linked to the degree of autonomy in the daily life of patients. It is considered significant effects on their Quality of Life(QOL).
Further methods of rehabilitation are required for convalescent patients to recover their function soon and better, due to a multitudes of recovery patient with troubles such as gait problem.
This trial is studying to investigate the effects of gait training with a functional electrical stimulation (FES) 'WalkAide[R](WA)' to improve the lower-limb function and ambulation in convalescent stroke patients.
Visão geral do estudo
Descrição detalhada
This study is targeting convalescent patients within 6 months after the onset of initial stroke (cerebral infarction or cerebral hemorrhage) and also observing the foot drop during walking.
Some study for the patients after the onset of stroke (over several months) are reported that a case of the efficacy by the treatment using the FES, and another case of using FES indicated the equal efficacy and the higher QOL compared to using ankle-foot orthosis(AFO).
However, these are clinical research results overseas and there are not so many studies targeting only for convalescent stroke patients.
FES which recover the lost function by paralysis using electrical stimulation is recommended as convalescent rehabilitation by Japanese Guidelines for the Management of Stroke 2015 etc..
The purpose of FES treatment is the electrical stimulation to peroneal nerve of patients with foot drop and equinus foot due to central nervous system damage and the objective efficacy is following:
- To improve the walking by dorsiflexing the foot during swing phase
- To prevention and suppression of disuse atrophy
- To increase local blood flow
- To re-educate muscle
- To maintain or increase the range of joint motion
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Chiba-prefecture
-
Yachiyo-city, Chiba-prefecture, Japão, 276-0015
- Shinyachiyo Hospital
-
-
Ehime-prefecture
-
Matsuyama-city, Ehime-prefecture, Japão, 791-1111
- Matsuyama Rehabilitation Hospital
-
-
Fukuoka-prefecture
-
Kurume-city, Fukuoka-prefecture, Japão, 830-0047
- St.Mary's Hospital Healthcare Center
-
Yame-city, Fukuoka-prefecture, Japão, 834-0006
- Yame Rehabilitation Hospital
-
-
Hokkaido-prefecture
-
Kitami-city, Hokkaido-prefecture, Japão, 090-0837
- Hokusei Memorial Hospital
-
Muroran-city, Hokkaido-prefecture, Japão, 050-0082
- Ohkawara Neurosurgical Hospital
-
Obihiro-city, Hokkaido-prefecture, Japão, 080-0833
- Tokachi Rehabilitation Center
-
Sapporo-city, Hokkaido-prefecture, Japão, 003-0026
- Sapporo Shiroishi Memorial Hospital
-
Sapporo-city, Hokkaido-prefecture, Japão, 060-0031
- Tokeidai Memorial Hospital
-
Sapporo-city, Hokkaido-prefecture, Japão, 060-0010
- Sapporo Keijinkai Rehabilitation Hospital
-
-
Hyogo-prefecture
-
Kobe-city, Hyogo-prefecture, Japão, 652-0803
- Yoshida Hospital, Cerebrovascular Research Institute
-
-
Kagoshima-prefecture
-
Aira-city, Kagoshima-prefecture, Japão, 899-5241
- Kajikionsen Hospital
-
Kagoshima-city, Kagoshima-prefecture, Japão, 890-0031
- Acras Central Hospital
-
Kagoshima-city, Kagoshima-prefecture, Japão, 890-8520
- Department of Rehabilitation and Physical Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University
-
Kanoya-city, Kagoshima-prefecture, Japão, 893-0023
- Kohshinkai Ogura Hospital
-
Tarumi-city, Kagoshima-prefecture, Japão, 891-2124
- Tarumi City Medical Center Tarumi Central Hospital
-
-
Kumamoto-prefecture
-
Kumamoto-city, Kumamoto-prefecture, Japão, 861-4173
- Sakura Jyuji Hospital
-
Kumamoto-city, Kumamoto-prefecture, Japão, 862-0924
- Kumamoto Takumadai Rehabilitation Hospital
-
-
Miyazaki-prefecture
-
Miyakonojo-city, Miyazaki-prefecture, Japão, 885-0072
- Fujimotokanmachi Hospital
-
Miyazaki-city, Miyazaki-prefecture, Japão, 880-2112
- Junwakai Memorial Hospital
-
Nichinan-city, Miyazaki-prefecture, Japão, 889-3141
- Nichinan Municipal Chubu Hospital
-
-
Nagasaki-prefecture
-
Sasebo-city, Nagasaki-prefecture, Japão, 857-0022
- Yohkoh Rehabilitation Hospital
-
Togitsu-cho, Nishisonogi-gun, Nagasaki-prefecture, Japão, 851-2103
- Nagasakikita Hospital
-
-
Okinawa-prefecture
-
Okinawa-city, Okinawa-prefecture, Japão, 904-2151
- Chuzan Hospital
-
Okinawa-city, Okinawa-prefecture, Japão, 904-2173
- Okinawa Rehabilitation Center Hospital
-
Shimajiri-gun, Okinawa-prefecture, Japão, 901-0493
- Nanbu-Tokushukai Hospital
-
-
Osaka-prefecture
-
Toyonaka-city, Osaka-prefecture, Japão, 560-0054
- Kansai Rehabilitation Hospital
-
-
Saitama-prefecture
-
Misato-city, Saitama-prefecture, Japão, 341-0034
- Saitama Misato Sogo Rehabilitation Hospital
-
-
Shizuoka-prefecture
-
Hamamatsu-city, Shizuoka-prefecture, Japão, 433-8511
- Seirei Hamamatsu City Rehabilitaion Hospital
-
-
Tokyo
-
Adachi-ku, Tokyo, Japão, 123-0864
- Hakujikai Memorial Hospital
-
Itabashi-ku, Tokyo, Japão, 174-0051
- IMS Itabashi Rehabilitation Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- 1) Patients who agree to participate in this study and provide their informed consent
- 2) Patients from 20 to 85 years old at the time of consent
- 3) Patients of convalescent stoke (within 6 months of onset)
- 4) Patients with a first episode of stroke, which type limited intracranial hemorrhage or ischemic stroke (excluding subarachnoid hemorrhage)
- 5) Patients inpatients for the rehabilitation therapy
- 6) Patients diagnosed 3 or 4 on Functional Ambulation Classification (FAC)
- 7) Patients stable general condition(blood pressure, pulse, blood glucose level etc.)
- 8) Patients with drop foot in walking
Exclusion Criteria:
- 1) Patients due to severe heart disease
- 2) Patients with previous gait disability, such as neurological disease
- 3) Patients with previous orthopedic disease, such as knee osteoarthritis
- 4) Patients with severe hepatic or renal dysfunction
- 5) Patients with severe sensory disturbance or severe ataxia or severe higher brain dysfunction
- 6) Patients correspond to contraindicated for the electrical stimulation (e.g. patients with a medical implant or implantable medical electrical equipment such as a cardiac pacemaker)
- 7) Patients with severe skin disease
- 8) Patients with any dose adjustment of antispasticity drugs (tizanidine hydrochloride, eperisone hydrochloride, baclofen, etc.) within 1month
- 9) Patients whose impairment severities changed during the study period
- 10) Patients taking the botulinum toxin formulation injection or the nerve block injection with phenol within 6months
- 11) Patients with any lower limb treatment using FES or the robot suit within 1month
- 12) Patients diagnosed not to use during the the WA trial operation period
- 13) Patients who do not complete the WA trial operation for 7 days
- 14) Patients joining any other clinical trials or studies with intervention
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Ao controle
|
Conventional rehabilitation therapy and gait training without WA.
|
|
Experimental: WA
|
Conventional rehabilitation therapy and gait training with WAIntervention with WA is scheduled 40min/day, five times a week, for 8 weeks.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
maximum walking distance of 6 Minute Walk Test (bare feet)
Prazo: 8weeks
|
Measuring maximum walking distance of 6 Minute Walk Test at baseline and after 8-weeks intervention.
Calculating difference of those measured values.
Targeting for all patients.
|
8weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
maximum walking distance of 6 Minute Walk Test (with WA)
Prazo: 8weeks
|
Measuring maximum walking distance of 6 Minute Walk Test at baseline and after 8-weeks intervention. Calculating difference of those measured values. Targeting only for WA group. |
8weeks
|
|
maximum walking distance of 6 Minute Walk Test (with AFO)
Prazo: 8weeks
|
Measuring maximum walking distance of 6 Minute Walk Test at baseline and after 8-weeks intervention. Calculating difference of those measured values. Targeting only for patients using AFO before starting this study. |
8weeks
|
|
walking speed of 10 Meter Walk Test (bare feet)
Prazo: 8weeks
|
Measuring maximum walking speed of 10 Meter Walk Test at baseline and after 8-weeks intervention.
Calculating difference of those measured values.
Targeting for all patients.
|
8weeks
|
|
walking speed of 10 Meter Walk Test (with WA)
Prazo: 8weeks
|
Measuring maximum walking speed of 10 Meter Walk Test at baseline and after 8-weeks intervention.
Calculating difference of those measured values.
Targeting only for WA group.
|
8weeks
|
|
walking speed of 10 Meter Walk Test (with AFO)
Prazo: 8weeks
|
Measuring maximum walking speed of 10 Meter Walk Test at baseline and after 8-weeks intervention.
Calculating difference of those measured values.
Targeting only for patients using AFO before starting this study.
|
8weeks
|
|
Fugl-Meyer assessment (FMA)
Prazo: 8weeks
|
Calculating difference of the total score of lower extremity subscale of the Fugl-Meyer Assessment (perfect score: 34 points) at baseline and after 8-weeks intervention.
|
8weeks
|
|
modified Ashworth scale (MAS)
Prazo: 8weeks
|
Calculating difference of the muscle tone six levels ( 0 , 1 , 1+ , 2 , 3 , 4 ) at baseline and after 8-weeks intervention.
|
8weeks
|
|
range of motion
Prazo: 8weeks
|
Calculating difference of the angle of the ankle succumbed back (5 ° increments) at baseline and after 8-weeks intervention.
|
8weeks
|
|
Timed up and go test (bere feet)
Prazo: 8weeks
|
Measuring the time that patients take to rise from a chair, walk three metres, turn around, walk back to the chair, and sit down . Calculating difference of those measured values between at baseline and after 8-weeks intervention. Targeting for all patients. |
8weeks
|
|
Timed up and go test (with AFO)
Prazo: 8weeks
|
Measuring the time that patients take to rise from a chair, walk three metres, turn around, walk back to the chair, and sit down . Calculating difference of those measured values between at baseline and after 8-weeks intervention. Targeting only for patients using AFO before starting this study. |
8weeks
|
|
Timed up and go test (with WA)
Prazo: 8weeks
|
Measuring the time that patients take to rise from a chair, walk three metres, turn around, walk back to the chair, and sit down . Calculating difference of those measured values between at baseline and after 8-weeks intervention. Targeting only for WA group. |
8weeks
|
|
Stroke Impact Scale (SIS)
Prazo: 8weeks
|
An evaluation of summation score of the total score and physical domain (sixth domain) score.
Calculating difference of those measured values between at baseline and after 8-weeks intervention.
|
8weeks
|
|
Patient reported outcome measure (PRO)
Prazo: 8weeks
|
Evaluation gait analysis using visual analogue scale(VAS scale) by Patient's own.
Calculating the difference of these VAS scale between at baseline and after 8-weeks intervention.
|
8weeks
|
|
gait analysis by medical staff
Prazo: 8weeks
|
Evaluation using total score of gait analysis by medical staff (-48~48).Calculating difference of these score between at baseline and after 8-weeks intervention.
|
8weeks
|
|
Adverse event assessment
Prazo: 8weeks
|
A frequency counting of the adverse events. LLT code will be assigned to the reported adverse event using the MedDRA dictionary. The origin date of the term until adverse events define the start date of the treatment program(0 week). Also doing a frequency counting of adverse events observed during the the WA trial operation period, but not included in the safety evaluation of the treatment program. |
8weeks
|
Colaboradores e Investigadores
Investigadores
- Cadeira de estudo: Shuji Matsumoto, MD, Ph.D, Nippon Medical School
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- TRIORTHO1524
- UMIN-CTR (Outro identificador: UMIN000020604)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .